Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Neurology
Study Phase : Phase III
Recipient : Formosa Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Formosa Pharmaceuticals Licenses APP13007 for Inflammation and Pain Post-Ocular Surgery
Details : Under the agreement, Cristália gets exclusive Brazilian rights for commercializing APP13007 (clobetasol propionate ophthalmic nanosuspension) for inflammation and pain following ocular surgery.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Undisclosed
January 26, 2024
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Recipient : Formosa Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : CRIS100
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety of CRIS100 on Treatment Spinal Cord Injury
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 22, 2023
Lead Product(s) : CRIS100
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bupivacaine
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hyperbaric Novabupi® in Spinal Anesthesia in Lower Limbs Vascular Surgery
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 21, 2019
Lead Product(s) : Bupivacaine
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Esmolol Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Esmolol for the Treatment of Hypertension After Intracerebral Hemorrhage Study (ETHICHS)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 15, 2018
Lead Product(s) : Esmolol Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amitriptyline
Therapeutic Area : Neurology
Study Phase : Phase III
Recipient : University of Sao Paulo
Deal Size : Inapplicable
Deal Type : Inapplicable
Treatment of Neuropathic Pain in Leprosy
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 27, 2017
Lead Product(s) : Amitriptyline
Therapeutic Area : Neurology
Highest Development Status : Phase III
Recipient : University of Sao Paulo
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ALT02
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Alteogen
Deal Size : Inapplicable
Deal Type : Inapplicable
A Comparing Study Between ALT02(Trastuzumab Biosimilar) and Herceptin® in Healthy Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 08, 2017
Lead Product(s) : ALT02
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Alteogen
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxybutynin
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Hospital Israelita Albert Einstein | University of Sao Paulo
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluate the Efficacy of Oxybutynin Chloride in Patients With Primary Hyperhidrosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 31, 2014
Lead Product(s) : Oxybutynin
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Hospital Israelita Albert Einstein | University of Sao Paulo
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Collagenase Inhibitor
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Newco Trials Pesquisa Científica Ltda
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluate the Noninferiority of Medicines Treating Uninfected Pressure Ulcers.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
December 09, 2013
Lead Product(s) : Collagenase Inhibitor
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Newco Trials Pesquisa Científica Ltda
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levobupivacaine
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Newco Trials Pesquisa Científica Ltda
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase III, Evaluate Noninferiority Between Levobupivacaine and Bupivacaine in Spinal Anesthesia.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 26, 2013
Lead Product(s) : Levobupivacaine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Newco Trials Pesquisa Científica Ltda
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Propofol
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Professor Fernando Figueira Integral Medicine Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 30, 2011
Lead Product(s) : Propofol
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Professor Fernando Figueira Integral Medicine Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
